Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma...

Area of Science:

• Pediatric oncology
• Cancer biology
• Drug discovery

Background:

• Medulloblastoma (MB) is a common pediatric brain tumor with high mortality.
• Aggressive subtypes, including SHH-driven and Group 3 MB, require novel therapeutic strategies.
• Disulfiram (DSF), an Aldehyde-Dehydrogenase (ALDH) inhibitor, and Copper (Cu++) present a potential new treatment avenue.

Purpose of the Study:

• To evaluate the safety and efficacy of DSF/Cu++ in pediatric medulloblastoma.
• To investigate the molecular mechanisms, including effects on cancer stem cells (CSCs) and DNA damage.
• To assess DSF/Cu++ in SHH-driven and Group 3 MB models.

Main Methods:

• Utilized ONS76, UW228, D425med, D283, and D341 cell lines for in vitro studies.
• Assessed cytotoxicity, anti-CSC effects, and molecular changes using assays like flow-cytometry and western-blotting.
• Evaluated in vivo efficacy, survival, and protein expression in Group 3 MB xenografts.

Main Results:

• DSF/Cu++ demonstrated significant in vitro cytotoxicity at nanomolar concentrations.
• Treatment induced cell death via NPL4 accumulation and poly-ubiquitylated protein buildup.
• A significant reduction in ALDH+, Nestin+, and CD133+ cells confirmed anti-CSC effects in vitro and in vivo, prolonging survival.

Conclusions:

• DSF/Cu++ exhibits potent anti-cancer activity against aggressive medulloblastoma subtypes.
• The combination therapy effectively reduces cancer stem cells and induces cell death.
• DSF/Cu++ represents a promising novel monotherapy or combination treatment for pediatric MB.